Should we incorporate obstructive sleep apnea in CHA2DS2-VASc score?


Journal

Sleep & breathing = Schlaf & Atmung
ISSN: 1522-1709
Titre abrégé: Sleep Breath
Pays: Germany
ID NLM: 9804161

Informations de publication

Date de publication:
12 2021
Historique:
received: 04 10 2020
accepted: 18 01 2021
revised: 10 01 2021
pubmed: 3 2 2021
medline: 5 3 2022
entrez: 2 2 2021
Statut: ppublish

Résumé

Atrial fibrillation (AF) is considered a significant challenge in cardiovascular medicine related to significant morbidity and mortality. Obstructive sleep apnea (OSA) is associated with stroke and constitutes an important risk factor for AF. However, it is still ambiguous whether OSA is independently related to stroke or systemic embolism in AF patients, and whether or not OSA should be included in CHA2DS2-VASc score. In a recent study, the presence of OSA in patients with AF was associated with higher rates of adverse events, namely stroke and systemic embolism. Patients with OSA have higher CHA2DS2-VASc scores and mean CHA2DS2-VASc scores that increase with OSA severity. The addition of OSA to CHA2DS2-VASc resulted in improved discrimination, but this improvement was modest and clinically non-significant. However, cardiovascular risk factors that accompany OSA and not OSA per se might be responsible for the increased thromboembolic risk in these patients. It is noteworthy that patients with OSA with CHA2DS2-VASc <2 had a higher incidence of stroke compared to those without. Unfortunately, the event rates for stroke in these patients were too low to reach statistically validated conclusions. Therefore, it seems reasonable to suggest that in borderline stroke risk patients (CHA2DS2-VASc <2), the presence of OSA should be taken into account in the treatment decision. More studies are needed to elucidate whether or not OSA should be incorporated in CHA2DS2-VASc score.

Identifiants

pubmed: 33527257
doi: 10.1007/s11325-021-02305-3
pii: 10.1007/s11325-021-02305-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2099-2101

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.

Références

Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988
doi: 10.1161/01.STR.22.8.983
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952
doi: 10.1161/01.CIR.98.10.946
Andersson T, Magnuson A, Bryngelsson IL, Frøbert O, Henriksson KM, Edvardsson N, Poçi D (2013) All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study. Eur Heart J 34:1061–1067
doi: 10.1093/eurheartj/ehs469
Goudis CA, Ketikoglou DG (2017) Obstructive sleep and atrial fibrillation: pathophysiological mechanisms and therapeutic implications. Int J Cardiol 230:293–300. https://doi.org/10.1016/j.ijcard.2016.12.120
doi: 10.1016/j.ijcard.2016.12.120 pubmed: 28040290
Youssef I, Kamran H, Yacoub M, Patel N, Goulbourne C, Kumar S, Kane J, Hoffner H, Salifu M, McFarlane SI (2018) Obstructive sleep apnea as a risk factor for atrial fibrillation: a meta-analysis. J Sleep Disord Ther 7:282. https://doi.org/10.4172/2167-0277.1000282
doi: 10.4172/2167-0277.1000282 pubmed: 29657903 pmcid: 5898401
Monahan K, Brewster J, Wang L, Parvez B, Goyal S, Roden DM, Darbar D (2012) Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol 110:369–372
doi: 10.1016/j.amjcard.2012.03.037
Mazza A, Bendini MG, Cristofori M, Nardi S, Leggio M, de Cristofaro R, Giordano A, Cozzari L, Giordano G, Cappato R (2009) Baseline apnoea/hypopnea index and high-sensitivity C-reactive protein for the risk of recurrence of atrial fibrillation after successful electrical cardioversion: a predictive model based upon the multiple effects of significant variables. Europace 11:902–909
doi: 10.1093/europace/eup107
Congrete S, Bintvihok M, Thongprayoon C, Bathini T, Boonpheng B, Sharma K, Chokesuwattanaskul R, Srivali N, Tanawuttiwat T, Cheungpasitporn W (2018) Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis. J Evid Based Med 11:145–151. https://doi.org/10.1111/jebm.12313
doi: 10.1111/jebm.12313 pubmed: 30091301
Deng F, Raza A, Guo J (2018 Jun) Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis. Sleep Med 46:5–11. https://doi.org/10.1016/j.sleep.2018.02.013
doi: 10.1016/j.sleep.2018.02.013 pubmed: 29773211
Yang Y, Ning Y, Wen W, Jia Y, Chen X, Huang M, Sara JD, Qin Y, Fang F, Zhang H, du Y, Li L, Jiao X, Yang Y, Han X, Zhang M, Wei Y (2020) CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a metaanalysis. J Interv Card Electrophysiol 58:369–379. https://doi.org/10.1007/s10840-020-00738-6
doi: 10.1007/s10840-020-00738-6 pubmed: 32472281
Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V (2005) Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353:2034–2041
doi: 10.1056/NEJMoa043104
Dalgaard F, North R, Pieper K, Fonarow GC, Kowey PR, Gersh BJ, Mahaffey KW, Pokorney S, Steinberg BA, Naccarrelli G, Allen LA, Reiffel JA, Ezekowitz M, Singer DE, Chan PS, Peterson ED, Piccini JP (2020) Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. Am Heart J 223:65–71. https://doi.org/10.1016/j.ahj.2020.01.001
doi: 10.1016/j.ahj.2020.01.001 pubmed: 32179257 pmcid: 7214210
Yaranov DM, Smyrlis A, Usatii N, Butler A, Petrini JR, Mendez J, Warshofsky MK (2015) Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. Am J Cardiol 115:461–465. https://doi.org/10.1016/j.amjcard.2014.11.027
doi: 10.1016/j.amjcard.2014.11.027 pubmed: 25529543
Mansukhani MP, Calvin AD, Kolla BP, Brown RD Jr, Lipford MC, Somers VK, Caples SM (2013) The association between atrial fibrillation and stroke in patients with obstructive sleep apnea: a population-based casecontrol study. Sleep Med 14:243–246. https://doi.org/10.1016/j.sleep.2012.08.021
doi: 10.1016/j.sleep.2012.08.021 pubmed: 23340087 pmcid: 3582732
Szymanski FM, Filipiak KJ, Platek AE, Hrynkiewicz-Szymanska A, Karpinski G, Opolski G (2015) Assessment of CHADS2 and CHA2DS2-VASc scores in obstructive sleep apnea patients with atrial fibrillation. Sleep Breath 19:531–537. https://doi.org/10.1007/s11325-014-1042-5
doi: 10.1007/s11325-014-1042-5 pubmed: 25084983
Platek AE, Szymanski FM, Filipiak KJ, Kotkowski M, Karpinski G, Opolski G (2016) Which components of the CHA2DS2-VASc score are the most important in obstructive sleep apnea patients with atrial fibrillation? Blood Coagul Fibrinolysis 27:347–351. https://doi.org/10.1097/MBC.0000000000000434
doi: 10.1097/MBC.0000000000000434 pubmed: 27023880
Platek AE, Szymanski FM, Filipiak KJ, Dudzik-Plocica A, Krzowski B, Karpinski G (2017) Stratification of cardiovascular risk in patients with atrial fibrillation and obstructive sleep apnea-validity of the 2MACE score. Sleep Breath 21:601–606. https://doi.org/10.1007/s11325-017-1469-6
doi: 10.1007/s11325-017-1469-6 pubmed: 28155102 pmcid: 5585292
Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Raña-Míguez P, Anguita M, Muñiz J, Cequier Á, Bertomeu-Martínez V, Valdés M, Vicente V, Lip GYH, Roldán V (2017) Usefulness of the 2MACE score to predicts adverse cardiovascular events in patients with atrial fibrillation. Am J Cardiol 120:2176–2181. https://doi.org/10.1016/j.amjcard.2017.09.003
doi: 10.1016/j.amjcard.2017.09.003 pubmed: 29111209
Chang CC, Chiu CC, Chiang CH, Huang CC, Chan WL, Huang PH, Chen YC, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB (2015) Obstructive sleep apnea and the risk of ischemic stroke in patients with atrial fibrillation. Int J Cardiol 181:144–146. https://doi.org/10.1016/j.ijcard.2014.12.019
doi: 10.1016/j.ijcard.2014.12.019 pubmed: 25497540

Auteurs

Christos Goudis (C)

Department of Cardiology, Serres General Hospital, Serres, Greece. cgoudis@hotmail.com.

Stylianos Daios (S)

Department of Cardiology, Serres General Hospital, Serres, Greece.

Panagiotis Korantzopoulos (P)

First Department of Cardiology, University of Ioannina Medical School, Ioannina, Greece.

Tong Liu (T)

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH